TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07073547: A Modular, Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120, a Dual-targeting Autologous Chimeric Antig

Sponsor: AstraZeneca · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 40 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$376,992

Rescue Site Savings

+$251,328

Unlock Full NCT07073547 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07073547 Rescue Dossier →